Navigation Links
BioElectronics and Pulsed Shortwave Therapy Make Progress
Date:5/23/2013

FREDERICK, Md., May 23, 2013 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of very effective, safe consumer medical devices, comments on the FDA panel meeting for non-thermal shortwave diathermy:

The FDA's Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting was held on May 21, 2013 in Gaithersburg, MD, USA.  The focus of the meeting was very narrow, in that the FDA had instructed the panel to focus solely on the application of non-thermal shortwave diathermy for the treatment of postoperative pain and edema and the treatment of edema following blepharoplasty.  Industry representatives, including BioElectronics President Andy Whelan , presented a compelling case for reclassification.  The recommendation from the FDA's advisory panel was reclassification from Class III to Class II with special controls including a requirement for new clinical data. At this time it is not clear if the requirement for new clinical data applies to existing products.  The FDA will make a final decision on the recommendations of the panel in due course, though BioElectronics believes that the FDA will follow the panel's recommendations.

"Overall, we see the advisory panel and the FDA's recommendations as a positive and potentially significant development," stated Ian Rawe , BioElectronics Director of Clinical Research.  "After decades of use and research, the FDA now believes that the available evidence suggests that shortwave devices can be safely regulated. If existing cleared devices are compelled to submit new clinical data, our 3rd Molar Extraction clinical study at Tufts Dental School, Boston, meets all the FDA's clinical research standards. This study is evaluating both postoperative pain and edema, with edema being quantified with a 3D digital imaging system (http://www.3dmd.com/). Therefore, because of these expected developments and with expanded clinical research in place we are confident of moving forward."

We also continue to press our Petitions in the FDA's Commissioner's Office of Science Integrity for our musculoskeletal and menstrual pain market clearances and we are optimistic that this reclassification concession will help expedite market clearances. 

About BioElectronics Corporation

BioElectronics (www.bielcorp.com) is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care.

Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com

 

 

 


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Presents FDA Reclassification Panel
2. BioElectronics New Patent Published
3. BioElectronics to Ease pain in Iraq
4. BioElectronics Selects New South Korean Distributor for its Healing and Pain Products
5. BioElectronics Obtains Additional US Patent For Its Unique Pain Devices
6. BioElectronics Enters Malaysias Pain Relief Market
7. BioElectronics Unique Pain Relief Product Featured on Leading Healthcare Show in Spain
8. BioElectronics Announces Chronic and Postoperative Wound Care Product Distribution in Italy
9. BioElectronics CEO Honored by Chabad at Johns Hopkins Medicine
10. BioElectronics Expands European Distribution to Malta
11. BioElectronics Announces Publication of Patent Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
Breaking Medicine News(10 mins):